CIA
JAZZ icon

CSat Investment Advisory’s Jazz Pharmaceuticals JAZZ Stock Holding History

CSat Investment Advisory’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-233
Closed -$33K – 741
2020
Q3 		$33K Buy
233
+28
+14% +$3.47K ﹤0.01% 741
2020
Q2 		$23K Buy
205
+24
+13% +$2.65K ﹤0.01% 797
2020
Q1 		$18K Buy
181
+33
+22% +$4.27K ﹤0.01% 747
2019
Q4 		$22K Buy
148
+18
+14% +$2.45K 0.01% 758
2019
Q3 		$17K Buy
130
+18
+16% +$2.41K 0.01% 752
2019
Q2 		$16K Buy
+112
New +$15.1K 0.01% 735

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CSat Investment Advisory's JAZZ Position: Q4 2020 in Review

CSat Investment Advisory sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2020, closing a stake of 233 shares — an estimated $33K sold.

CSat Investment Advisory first reported a position in JAZZ in Q2 2019 and held it in 6 quarters. The position peaked at $33K in Q3 2020. 437 funds tracked by Wall St. Rank hold JAZZ as of Q4 2020.

  • CSat Investment Advisory reported no remaining Jazz Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 233 Jazz Pharmaceuticals shares in Q4 2020, an estimated $33K.
  • CSat Investment Advisory first reported a position in Jazz Pharmaceuticals in Q2 2019 and held it in 6 quarters.
  • CSat Investment Advisory's Jazz Pharmaceuticals position peaked at $33K in Q3 2020.
  • 437 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.